- Home
- SVRA vs KURA Comparison
SVRA vs KURA Comparison
Compare SVRA & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- KURA
- Stock Information
- Founded
- SVRA 2007
- KURA 2014
- Country
- SVRA United States
- KURA United States
- Employees
- SVRA N/A
- KURA N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVRA Health Care
- KURA Health Care
- Exchange
- SVRA Nasdaq
- KURA Nasdaq
- Market Cap
- SVRA 528.3M
- KURA 561.9M
- IPO Year
- SVRA N/A
- KURA N/A
- Fundamental
- Price
- SVRA $2.21
- KURA $5.86
- Analyst Decision
- SVRA Buy
- KURA Strong Buy
- Analyst Count
- SVRA 5
- KURA 12
- Target Price
- SVRA $5.60
- KURA $24.50
- AVG Volume (30 Days)
- SVRA 1.2M
- KURA 1.3M
- Earning Date
- SVRA 08-11-2025
- KURA 08-07-2025
- Dividend Yield
- SVRA N/A
- KURA N/A
- EPS Growth
- SVRA N/A
- KURA N/A
- EPS
- SVRA N/A
- KURA N/A
- Revenue
- SVRA N/A
- KURA $67,991,000.00
- Revenue This Year
- SVRA N/A
- KURA $109.86
- Revenue Next Year
- SVRA N/A
- KURA $107.90
- P/E Ratio
- SVRA N/A
- KURA N/A
- Revenue Growth
- SVRA N/A
- KURA N/A
- 52 Week Low
- SVRA $1.89
- KURA $5.41
- 52 Week High
- SVRA $5.11
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- SVRA 41.30
- KURA 45.15
- Support Level
- SVRA $1.98
- KURA $5.58
- Resistance Level
- SVRA $2.29
- KURA $6.00
- Average True Range (ATR)
- SVRA 0.14
- KURA 0.25
- MACD
- SVRA 0.02
- KURA -0.04
- Stochastic Oscillator
- SVRA 42.19
- KURA 26.27
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.